July 1, 2006 |
The first generic versions of Zoloft received federal approval. Israel's Teva Pharmaceutical Industries Ltd. said it would make generic versions of the antidepressant in 25-, 50- and 100-milligram tablets. Roxane Laboratories Inc., based in Columbus, Ohio, would make a liquid concentrate version of the drug, the Food and Drug Administration said. Pfizer Inc.'s patent on Zoloft expires today.
May 26, 2006 |
Israel-based Teva Pharmaceutical Industries Ltd. won tentative U.S. regulatory approval to sell copies of Merck & Co.'s Zocor cholesterol drug, and said sales might start in June. Still at issue is the ability of Teva, the world's biggest generic drug maker, to sell the pills exclusively for six months under a U.S. rule designed to promote cheaper generics.
May 20, 2006 |
The nation's largest pharmacy benefits manager announced Friday that it was distributing more generic drugs than brand-name counterparts, a sign that costly brand-name prescription medicines may be losing their grip on the market, leading to lower drug costs for consumers. The trend is significant because even more generic prescription drugs are expected to hit the market in the near future.
March 7, 2006 |
GlaxoSmithKline lost a bid to prevent sales of generic versions of its $900-million-a-year allergy drug Flonase. Boehringer Ingelheim's generic version could reach the market today after U.S. District Judge Andre Davis in Baltimore refused to block sales while Glaxo pursues a lawsuit against the Food and Drug Administration.
January 4, 2006 |
Allergan Inc. said it won a ruling temporarily blocking Apotex Inc. from making or selling a generic version of a treatment for eye inflammation. The ruling, issued Dec. 29 by U.S. District Judge Martin Jenkins in San Francisco, temporarily prohibits Apotex from manufacturing or selling a generic version of Allergan's Acular in the U.S., Allergan spokeswoman Caroline Van Hove said. Irvine-based Allergan, which also makes the anti-wrinkle drug Botox, sued Apotex over patents for Acular in 2001.
September 7, 2005 |
Barr Pharmaceuticals Inc. and Teva Pharmaceutical Industries Ltd. said they would cooperate in launching generic versions of Sanofi-Aventis' Allegra allergy drug. Barr of Pomona, N.Y., received final approval last week for the generic drug from the Food and Drug Administration. Allegra sales were worth $1.4 billion for the 12 months ended in June, according to research firm IMS Health.
August 24, 2005 |
Generic-drug makers including Ivax Corp. and Teva Pharmaceutical Industries Ltd. aren't infringing patents on Pfizer Inc.'s epilepsy drug Neurontin by selling low-cost versions, a federal judge ruled. U.S. District Judge John Lifland in Newark, N.J., said the generic version of gabapentin, the key ingredient in Neurontin, didn't infringe. Pfizer will appeal, spokesman Paul Fitzhenry said. Teva, Ivax and Alpharma Inc.
August 9, 2005 |
Mabel Stoltz, at 93, lives independently in her own home in a quiet harbor town on the Minnesota shore of Lake Superior. But she has to watch her budget carefully and has been buying prescription drugs from Canada. So Stoltz was surprised to learn recently that she could buy her generic-label medications for much less from a U.S. pharmacy -- a potential savings of $560 a year for two prescriptions.
June 7, 2005 |
Pfizer Inc. and other drug companies have the right to sell unbranded versions of their own drugs even if they undercut sales of generic competitors, a U.S. appeals court has ruled. Teva Pharmaceutical Industries Ltd., the world's biggest generic-drug maker, sued in August to stop Pfizer from selling a lower-cost version of the epilepsy drug Neurontin. The U.S. Court of Appeals for the District of Columbia Circuit, in a ruling Friday, said the law didn't prohibit such "authorized generics."
April 15, 2005 |
A federal judge Thursday turned away the claims of generic drug manufacturers and ruled valid a patent for Eli Lilly & Co.'s drug Zyprexa. U.S. District Judge Richard Young in Indianapolis ruled in favor of Lilly on all of the matters in dispute in the case, Lilly said. However, appeals are likely. The ruling is a huge relief to Lilly, Chief Executive Sidney Taurel said.